Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 115.65
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Smruthi Organics Ltd. engages in the manufacture and sale of bulk drugs and drug intermediates. Its products include amlodipine besilate, amisulpride, carbidopa, ciprofloxacin, diloxanide furoate, fenofibrate, metformin hydrochloride, norfloxacin, pefloxacin, telmisartan, amlodipine base, and phthaloyl amlodipine. The company was founded by Purushotham Mallayya Eaga on July 11, 1989 and is headquartered in Solapur, India.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITD.
Data is available to registered users only
Buy
Sell